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Abstract: The insulin-like growth factor-binding protein 1 (IGFBP-1) is a 
member of a family of six homologous proteins that regulate the action of the 
insulin-like growth factors. IGFBP-1 is a 25 kDa protein that, in addition to its 
native form, may exist in several phosphoforms (30 kDa), which are predo-
minant in the circulation of humans. Phosphorylation of IGFBP-1 is a post- 
-translational modification that has a great influence on the action of IGF-I. 
IGFBP-1 forms multimers and complexes with α2-macroglobulin (α2M). Poly-
merisation of IGFBP-1 was also reported. In order to analyse and separate 
these IGFBP-1 molecular species, affinity chromatography methods were used 
in this study. The results demonstrated that most of the IGFBP-1 circulates in 
complexes with α2M, which can be isolated by affinity chromatography using 
immobilised anti-α2M antibodies. IGFBP-1/α2M complexes may be differen-
tiated from IGFBP-1 dimer and multimers using lectin-affinity chromatogra-
phy, since the latter do not interact with lectins. It seems that the complexes 
contain not only monomeric IGFBP-1, but also its multimers. The dimer and 
multimers are stable under reducing conditions, suggesting a covalent linkage 
between the units. Free IGFBP-1 monomer can be separated from multimers 
using Con A-affinity chromatography. The concentration of free IGFBP-1 is 
relatively low in the circulation. 
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INTRODUCTION 
Insulin-like growth factors (IGF-I and IGF-II) are polypeptides, which regu-
late cell growth, differentiation and metabolism.1 In the circulation they are asso-
ciated with IGF binding proteins (IGFBPs), a family that consists of six homo-
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logous proteins that modulate the bioactivity of IGFs. IGFBPs can either inhibit 
or enhance the activity of IGFs or have IGF independent effects.2 Only the free 
(unbound) form of IGF is considered to be biologically active.3 
IGFBP-1 is synthesised in many cell types, including hepatocytes, ovarian 
granulose cells, decidualised endometrium2 and cells of connective tissue.4 It is 
the predominant binding protein in amniotic fluid. In healthy individuals, the 
concentration of circulating IGFBP-1 fluctuates tenfold or more within a few 
hours as a response to changes in insulin concentration.3 The concentrations of 
insulin and IGFBP-1 alter in opposite directions. 
IGFBP-1 is a 25 kDa protein that may exist in several phosphoforms of ap-
proximately 30 kDa.5 Up to five IGFBP-1 forms, varying in the degree of phos-
phorylation, have been identified.6,7 Numerous studies have indicated that human 
IGFBP-1 may both potentiate or inhibit IGF-I stimulated biological activity.8,9 
The differences in IGFBP-1 actions are due to differential phosphorylation of 
IGFBP-1 that alters its affinity for IGF-I.10 Potential phosphorylation sites of hu-
man IGFBP-1 are Ser101, Ser119 and Ser169.9 Highly phosphorylated IGFBP-1 
is the predominant isoform of IGFBP-1 in the circulation of a healthy adult, ha-
ving affinity for IGF-I that is six- to eightfold higher than that of non-phos-
phorylated IGFBP-1.11 Since the non-phosphorylated form binds IGF-I less tight-
ly, enhancing its actions,9,11 a delicate equilibrium between phosphorylated and 
non-phosphorylated isoforms is responsible for the regulation of IGF-I activity. 
In the circulation, IGFBP-1 associates with the glycoprotein α2-macroglo-
bulin (α2M, ≈700 kDa), which protects IGFBP-1 from proteolysis.6 Thus, the 
IGFBP-1/α2M complex may have an important role in controlling IGF-I action 
by regulating the amount of free IGFBP-1. In tissues, IGFBP-1 was found to form 
multimers, the role of which in the action of IGF remains to be determined.12 
The aim of this study was to investigate IGFBP-1 isoforms, multimers and 
complexes in the circulation of healthy persons, using different affinity chroma-
tography matrices. The affinity chromatography methods were based on the fol-
lowing interactions: metal ion–phosphoprotein, antigen–antibody and lectin–gly-
coprotein. 
EXPERIMENTAL 
Samples 
Blood samples were obtained from healthy adult volunteers (n = 10). Venous blood was 
collected after 12 h fasting. The serum was separated by centrifugation within 45 min and kept 
frozen at –20 °C until used. The study was approved by the local ethics committee of the 
Institute for the Application of Nuclear Energy. 
Immobilised metal-affinity chromatography (IMAC) 
Iminodiacetic acid-agarose (IDA) was purchased from Sigma-Aldrich (Steinheim, Ger-
many) and 1 mL of gel was packed into a column. After the column had been washed with 
distilled water, 1.0 mL of 0.10 mol L-1 ferric chloride solution was applied in order to saturate 
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the column with ferric ions. Unbound metal ions were washed out with 5 ml of distilled water 
and 5 ml of 0.1 % acetic acid. The column was equilibrated with dilution buffer: 0.05 mol L-1 
MES (2-(N-morpholino)ethanesulphonic acid)/0.5 mol L-1 NaCl buffer pH 5.5.13 Serum samples 
(100 μL diluted in 900 μL of dilution buffer) were circulated through the column for 1 h to 
ensure maximal binding. The unbound material was washed out with 5 mL of MES buffer. 
Elution of the bound molecules was performed using 8 mL of 0.2 mol L-1 Na-phosphate buf-
fer pH 8.0. The column was regenerated using 10 mL of 0.1 mol L-1 Na-borate/1.0 mol L-1 
NaCl buffer pH 10.0 and 10 mL of distilled water, followed by saturation with ferric chloride. 
The collected fractions (1.0 mL each) were kept at –20 °C until electrophoresis and immuno-
blotting were performed. 
Immunoaffinity chromatography (IgY-C) 
An IgY-12 column (1.2 mL of microbeads) was purchased from Beckman Coulter (Ful-
lerton, USA, Proteomelab IgY-12 High Capacity Proteome Partitioning kit). The matrix with 
immobilised antibodies enables the binding and removal of albumin, IgG, IgA, IgM, α1-an-
titrypsin, haptoglobin, transferrin, orosomucoid, α2M, HDL (apo A-I and apo A-II) and fib-
rinogen. The IgY column was loaded with 20 μL of serum diluted with 480 μL of dilution 
buffer: 10 mmol L-1 Tris (tris(hydroxymethyl)aminomethane)–HCl/1 mol L-1 NaCl buffer pH 
7.4, and incubated for 15 min at room temperature using a rotator.14 Unbound proteins were 
separated by centrifugation for 30 s at 2000 × g and the column was washed three times with 
dilution buffer. Bound proteins were eluted with 500 μL of elution buffer: 0.1 mol L-1 glyci-
ne–HCl buffer pH 2.5, for 3 min at room temperature using a rotator. They were separated 
from the gel by centrifugation and immediately neutralised with 50 μL of 1 mol L-1 Tris–HCl 
buffer pH 8.0. The column was washed three times with the elution buffer, neutralised with 
600 μL of 2 mol L-1 Tris–HCl buffer pH 8.0 and washed with a dilution buffer prior to the 
next chromatographic cycle. The collected fractions (1 mL each) were kept at –20 °C until 
electrophoresis and immunoblotting were performed. 
Lectin-affinity chromatography (LAC) 
Eleven agarose-immobilised lectins purchased from Vector Laboratories (Burlingame, 
CA, USA) were packed into columns: Con A (lectin from Canavalia ensiformis), SNA (Sam-
bucus nigra agglutinin), RCA-I (Ricinus communis agglutinin I), PHA-E (Phaseolus vulgaris 
erythroagglutinin), PHA-L (Phaseolus vulgaris leukoagglutinin), WGA (wheat germ aggluti-
nin), succinylated WGA, ECL (Erythrina cristagalli lectin), UEA (Ulex europaeus aggluti-
nin), LCA (Lens culinaris agglutinin) and MAL (lectin from Maackia amurensis). All co-
lumns except Con A- and LCA-agarose were equilibrated in 0.01 mol L-1 HEPES buffer, con-
taining 0.15 mol L-1 NaCl, 0.8 g L-1 NaN3, pH 7.5 (HBS). The Con A-agarose was equilib-
rated in 0.02 mol L-1 HEPES buffer containing 0.5 mol L-1 NaCl, 0.8 g L-1 NaN3, 1.0 mmol L-1 
CaCl2, MgCl2 and MnCl2, pH 7.5, whereas the LCA-agarose was equilibrated in 0.01 mol L-1 
HBS containing 0.8 g L-1 NaN3, 0.1 mmol L-1 CaCl2 and 0.01 mmol L-1 MnCl2, pH 7.5. The 
HBS used for ECL-, SNA-, UEA- and MAL-agarose equilibration contained 0.1 mmol L-1 
CaCl2, whereas the HBS used for the equilibration of PHA-E and PHA-L-agarose contained 
0.1 mmol L-1 CaCl2 and 0.01 mmol L-1 MnCl2. The pH of the HBS for the PHA-E-agarose 
equilibration was 8.0. Serum samples (100 μL diluted with 900 μL of the corresponding HBS) 
were circulated through the columns for 1 h. The unbound material was washed out with 20 
mL of the appropriate HBS. The elution of the bound glycoproteins was generally performed 
in two consecutive steps: 1) neutral elution using hapten sugar dissolved in 15 mL of the ap-
propriate HBS, pH 7.5 and 2) acidic elution with 7 mL of hapten sugar solution in 0.1 M 
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acetic acid, pH 3.0. The PHA-E and PHA-L-agarose columns were eluted in one-step only, 
using 10 mL of a 0.1 mol L-1 acetic acid solution. The hapten sugars used for specific elutions 
were: 0.5 mol L-1 lactose for MAL- and SNA-agarose, a mixture of 0.2 mol L-1 methyl-α-glu-
copyranoside and 0.2 mol L-1 methyl-α-mannopyranoside for Con A- and LCA-agarose, 0.2 
mol L-1 lactose for the RCA I- and ECL-agarose, 0.5 mol L-1 N-acetyl-glucosamine for the 
WGA- and succinylated WGA-agarose and 0.1 mol L-1 fructose for the UEA-agarose.15 The 
most concentrated protein fractions (1 ml each) were collected and the acidic fractions were 
immediately neutralised using 150 μL of 2 mol L-1 Tris–HCl buffer pH 8.9. The fractions 
were dialysed first against distilled water for 3 h at room temperature and then against 0.15 
mol L-1 NaCl overnight at 4 °C. After being concentrated to approximately 1.0 ml on Micro-
con centrifugal filter device (Millipore, Billerica, MA, USA) with a 10 kDa cut-off mem-
brane, the samples were kept frozen at –20 °C until electrophoresis and immunoblotting. 
Electrophoresis and Western immunoblotting (WIB) 
The most concentrated protein fractions obtained after affinity chromatography were 
subjected to: native polyacrylamide gel electrophoresis (nPAGE), denaturing non-reducing 
sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) and denaturing 
reducing SDS-PAGE with 10 % 2-mercaptoethanol (v/v) in the sample buffer (rSDS-PAGE) 
using 12 % gels.16 
Immunoblotting was performed using goat polyclonal anti-IGFBP-1 antiserum (DSL, 
Webster, USA), followed by an anti-goat IgG antibody coupled to horseradish peroxidase 
(Biosource, Camarillo, CA, USA) and a rabbit polyclonal anti-α2M antibody (IgG fraction, 
AbD Serotec, Oxford, UK), followed by an anti-rabbit IgG antibody coupled to horseradish 
peroxidase (Pierce Biotechnology, Rockford, IL, USA). The immunoreactive proteins were 
visualised using an enhanced chemiluminescence (ECL) reagent kit (Pierce, Minneapolis, 
MN, USA).16 Molecular mass markers were from BioRad Laboratories (Hertfordshire, UK) 
and the cytosol from human placental cells was used as a source of a physiological marker of 
IGFBP-1.17 
RESULTS AND DISCUSSION 
Several post-translational modifications are known to modify the affinity of 
IGFBPs for IGFs, including phosphorylation,7,18 proteolysis19 and polymerisa-
tion.20 The mechanisms accounting for these changes remain to be elucidated.12 
Phosphorylation of human IGFBP-1 leads to inhibition of IGF-I action.9,11 The 
non-phosphorylated isoform forms multimers more rapidly and to a greater ex-
tent compared to the phosphorylated isoform.12 When complexed to α2M, 
IGFBP-1 is protected from proteolysis, but still able to bind IGFs and, thus may 
be expected to influence the IGF action as well.6  
In order to assess the importance of various molecular forms of IGFBP-1, it 
is crucial to develop analytical tools for their investigation. To fulfil this goal, 
affinity chromatography methods based on three types of molecular recognition, 
i.e., IMAC, immunoaffinity chromatography and LAC, were employed. Electro-
phoretic separation followed by immunoblotting of the fractionated proteins was 
used to identify the different molecular forms of IGFBP-1. Fractions of all serum 
samples were subjected to SDS-PAGE, rSDS-PAGE and nPAGE. Since all 
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samples showed the same pattern of IGFBP-1 distribution upon immunoblotting, 
only the representative results are shown in the figures. 
SDS-PAGE revealed that almost all immunoreactive IGFBP-1 forms bound 
to the IDA column (Fig. 1a). Anti-IGFBP-1 antibodies recognised high molecular 
mass species as a very wide protein band (or several bands that could not be 
clearly distinguished) at ≈100 kDa, a protein at ≈60 kDa together with proteins at 
the start. IGFBP-1 monomer (≈30 kDa) was hardly visible. Matrices with immo-
bilised IDA and chelated ions are widely used for the isolation of phosphopro-
teins.13 Phosphate groups are electron-donors and, hence, can serve as ligands for 
coordination of metal ions. Ions that have the greatest affinity for binding to 
phosphoproteins are Fe3+, Ga3+ and Ni2+, Fe3+ being the most widely used metal 
ion in IMAC.13,21,22 According to the presented results, different molecular 
species of IGFBP-1 could not be separated using IMAC, since all of them bound 
to the matrix. rSDS-PAGE was performed in order to investigate the stability of 
IGFBP-1 complexes in the presence of 2-mercaptoethanol. Almost all high mole-
cular mass complexes, both in the bound and unbound fractions, dissociated, 
which resulted in the appearance of proteins of predominantly ≈60 and ≈30 kDa 
(Fig. 1b). This result implicates the existence of disulphide bonds that maintain 
molecules within the complex. It also suggests that the ≈ 60 kDa form is stable 
and resists dissociation into IGFBP-1 monomers. nPAGE was performed aiming 
to differentiate between the phosphoforms of IGFBP-1 monomer. Unfortunately, 
all isoforms appeared clustered in the middle of the gel and they could not be 
clearly separated from one another (Fig. 1c). Only proteins at the start were iden-
tified by immunoblotting with anti-α2M antibodies (Fig. 1d), suggesting that these 
species of very high molecular mass were IGFBP-1/α2M complexes. Cytosol 
 
Fig. 1. Immunoblotting of the unbound (UB) and bound (B) fractions obtained after IMAC 
with anti-IGFBP-1 antibodies after a) SDS-PAGE, b) rSDS-PAGE c) nPAGE, as well as 
with anti-α2M antibodies after d) SDS-PAGE. IGFBP-1 from placental cytosol (C) 
was used as a physiological marker. The positions of the molecular 
mass markers are indicated on the right side. 
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gave a different protein profile than that of serum, mostly in terms of the inten-
sity of the bands, as it contains a different proportion of IGFBP-1 molecular 
forms than serum. The positions of some protein bands in the two types of samp-
les varied slightly due to a difference in sample milieu (the number and abun-
dance of other proteins). 
After IgY-C, proteins in the bound fraction were identified as at least three 
bands of high molecular mass (Fig. 2a), one band at ≈60 kDa and a weak band at 
≈30 kDa. In the unbound fraction, high molecular mass bands appeared together 
with monomer IGFBP-1. In rSDS-PAGE (Fig. 2b) high molecular mass species 
dissociated giving predominantly a ≈60 kDa protein band in the bound fraction 
and a ≈30 kDa protein band in the unbound fraction. nPAGE (Fig. 2c), again, 
proved itself not to be useful for the study of the isoform pattern of IGFBP-1. 
Immunoblotting with anti-α2M antibodies (Fig. 2d) confirmed that only proteins 
at the start of the gel were IGFBP-1/α2M complexes. 
 
Fig. 2. Immunoblotting of unbound (UB) and bound (B) fractions obtained after IgY-C with 
anti-IGFBP-1 antibodies after a) SDS-PAGE, b) rSDS-PAGE c) nPAGE, as well as with anti-
α2M antibodies after d) SDS-PAGE. IGFBP-1 from placental cytosol (C) was used as a phy-
siological marker. The positions of the molecular mass markers are indicated on the right side. 
The IgY matrix contains immobilised antibodies against α2M and, according 
to the intensity of the stained protein band, the majority of IGFBP-1 in circu-
lation is engaged in complex formation with α2M. The presence of other protein 
bands in the bound fraction after SDS-PAGE was most likely due to the disso-
ciation of complexes either during the elution of the sample (acidic buffer) and/or 
during sample preparation for electrophoresis. Since anti-α2M antibodies recog-
nised only proteins positioned at the start, the immunoreactive bands of ≈100 and 
≈60 kDa do not contain fragments of α2M. These proteins are likely to be multi-
mers of IGFBP-1. The immunoreactive band of ≈60 kDa most likely represents 
dimeric IGFBP-1, the formation of which may be catalysed by a transglutami-
nase.12 To date, dimers were identified only in tissues consisting predominantly 
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of the non-phosphorylated IGFBP-1 form. IGFBP-1 forms having a mass greater 
than 60 kDa are most likely higher multimers, resisting the reduction by 2-mer-
captoethanol. Multimers of ≈100 kDa were also found in tissues.12 
Another way to differentiate IGFBP-1 complexes with α2M from IGFBP-1 
multimers is to employ lectins. Lectins have become very important analytical 
tool in glycoproteomics.23 In the present study, complexes of IGFBP-1 with gly-
coprotein α2M were expected to interact with certain lectins, whereas IGFBP-1 
multimers were not, since IGFBP-1 is not glycosylated. The reactivity was tested 
with eleven immobilised lectins covering a wide range of saccharide specificity. 
IGFBP-1 immunoreactive forms were detected in pH 7.5 eluates from: Con A-, 
SNA-, RCA-I- and WGA-agarose as well as in pH 3.0 eluates from Con A- and 
PHA-E-agarose (Fig. 3a). As expected, anti-IGFBP-1 antibodies recognised only 
the high molecular mass species (complexes with α2M). 
 
Fig. 3. Immunoblotting with anti-IGFBP-1 antibodies of the bound fractions obtained after 
LAC and SDS-PAGE. a) The presented samples were eluted from: Con A-agarose (pH 7.5 
and 3.0; lanes 1 and 2), SNA-agarose (pH 7.5; lane 3), RCA-I-agarose (pH 7.5; lane 4), 
PHA-E-agarose (pH 3.0; lane 5) and WGA-agarose (pH 7.5; lane 6); b) The presented 
samples were eluted from Con A-agarose: in the presence of Ca2+, Mn2+ and Mg2+ (pH 7.5 
and 3.0; lanes 1 and 2), in the presence of Ca2+ and Mg2+ (pH 7.5 and 3.0; lanes 3 and 4), 
in the presence of Ca2+ and Mn2+ (pH 7.5 and 3.0; lanes 5 and 6) and in the presence of 
Mn2+ and Mg2+ (pH 7.5 and 3.0; lanes 7 and 8). IGFBP-1 from placental cytosol (C) 
was used as a physiological marker. The positions of the molecular mass markers are 
indicated on the right side. 
Despite the fact that IGFBP-1 is not glycosylated at all, it bound to Con A 
and was eluted with the pH 3.0 buffer (Fig. 3a, lane 2). In order to investigate 
further the nature of this interaction, a series of experiments were performed by va-
rying the presence of ions required for Con A activation (Ca2+, Mn2+ and Mg2+). 
It was demonstrated that all three ions are necessary for the interaction between 
IGFBP-1 and Con A (Fig. 3b). The absence of Mg2+ and Mn2+ reduced the bind-
ing of IGFBP-1 to some extent, while the absence of Ca2+ inhibited the interact-
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tion completely. Lectin Con A is a metalloprotein, the 3D structure of which can 
adopt two conformational states, a “locked” form and an “unlocked” form.24 The 
unlocked form of Con A weakly binds metal ions and a saccharide ligand, while 
the locked form binds two metal ions per monomer, enabling its full binding ca-
pacity for the saccharide. Many metastable complexes can be formed as well. Bi-
nary, ternary and quaternary complexes having both Con A conformers were iden-
tified.25 Although Con A preferably binds methyl α-D-mannopyranoside and α-D-
mannosyl groups, the synthesised ligand peptides, which structurally imitate these 
saccharides, can also bind to this lectin.26 The specificity of Con A is not limited 
to saccharide units, but sugar-mimics may be identified by Con A binding sites as 
well. Therefore, the binding of IGFBP-1 monomer to Con A-agarose could be 
explained in the light of the appropriate conformational recognition. Metal ions, 
especially Ca2+, are crucial for the interaction to occur. 
CONCLUSIONS 
The results obtained in this study demonstrated that most of the IGFBP-1 
circulates associated with α2M. These complexes can be isolated by affinity chro-
matography with immobilised anti-α2M antibodies. IGFBP-1/α2M complexes 
may be differentiated from IGFBP-1 dimer and multimers using lectin-affinity 
chromatography, since the latter do not interact with lectins. It seems that the 
complexes contain not only monomeric IGFBP-1, but also its multimers. Dimer 
and multimers are stable under reducing conditions, suggesting covalent linkage 
between the units. Free IGFBP-1 monomer can be separated from the multimers 
using Con A-affinity chromatography. The concentration of free IGFBP-1 in cir-
culation is relatively low. 
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ИЗВОД 
ИСПИТИВАЊЕ РАЗЛИЧИТИХ IGFBP-1 МОЛЕКУЛСКИХ ФОРМИ ПРИМЕНОМ 
АФИНИТЕТНЕ ХРОМАТОГРАФИЈЕ СА ИМОБИЛИЗОВАНИМ МЕТАЛНИМ ЈОНОМ, 
АНТИТЕЛИМА И ЛЕКТИНИМА 
ДРАГАНА ЛАГУНЏИН, РОМАНА МАСНИКОСА, ГОРАН МИЉУШ, ДРАГАНА РОБАЈАЦ и ОЛГИЦА НЕДИЋ 
Institut za primenu nuklearne energije – INEP, Univerzitet u Beogradu, Banatska 31b, 11080 Beograd 
Везујући протеин тип 1 за инсулину сличне факторе раста (IGFBP-1) је члан фамилије 
која  садржи  шест  хомологих  везујућих  протеина,  чија  је  улога  у  регулацији  активности 
инсулину сличних фактора раста. IGFBP-1 је протеин од 25 kDa, који осим нативне, може 
постојати и у облику неколико фосфоформи (30 kDa), које доминирају у циркулацији људи. 
Фосфорилoвање IGFBP -1 је пост-транслациона модификација која има велики утицај на ак-
тивност IGF-I. IGFBP-1 формира мултимере и комплексе са α2-макроглобулином (α2M). У 
циљу анализе и раздвајања IGFBP-1 молекулских врста, у овом раду су примењене методе 
афинитетне хроматографије. Резултати су показали да се већина IGFBP-1 у циркулацији на-
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лази у комплексима са α2M, који се могу изоловати применом афинитетне хроматографије са 
имобилизованим анти-α2M антителима. IGFBP-1/α2M комплекси се могу раздвојити од 
IGFBP-1 димера и мултимера применом афинитетне хроматографије са имобилизованим ле-
ктинима, пошто се олигомери не везују за лектине. Димерна форма и мултимери су стабилни 
при  редукционим  условима,  што  указује  на  ковалентну  везу  између  јединица.  Слободни 
IGFBP-1 мономер је присутан у релативно малој концентрацији у циркулацији и може се 
раздвојити од мултимера применом афинитетне хроматографије са имобилизованим лекти-
ном Con A. 
(Примљено 30. марта, ревидирано 2. јула 2010) 
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